Last update 23 Jun 2025

I-Mab Biopharma US Ltd.

Subsidiary Company|2018|Maryland, United States|
www.i-mabbiopharma.com

Overview

Tags

Neoplasms
Digestive System Disorders
Other Diseases
Bispecific antibody
Fc fusion protein
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Immune System Diseases2
Endocrinology and Metabolic Disease2
Nervous System Diseases1
Hemic and Lymphatic Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Fc fusion protein1
Bispecific antibody1
Monoclonal antibody1
Top 5 TargetCount
4-1BB x CLDN18.21
C5AR1(C5a anaphylatoxin chemotactic receptor)1
IL-7Rα(Interleukin-7 receptor subunit alpha)1

Related

3
Drugs associated with I-Mab Biopharma US Ltd.
Efineptakin alfa (Genexine)
Target
IL-7Rα
Mechanism
IL-7Rα agonists
Active Org.
NeoImmuneTech, Inc.NeoImmuneTech, Inc. [+8]
Originator Org.
Genexine, Inc.Genexine, Inc.
Active Indication
Glioblastoma, IDH-Wildtype [+28]
Inactive Indication
Advanced Gastroesophageal Junction Adenocarcinoma [+14]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
Izastobart
Target
C5AR1
Mechanism
C5AR1 antagonists
Active Org.
Human Immunology Biosciences, Inc.Human Immunology Biosciences, Inc.
 [+3]
Originator Org.
MorphoSys AGMorphoSys AG
Active Indication
Autoimmune Diseases [+2]
Inactive Indication
Advanced cancer [+1]
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
Givastomig
Target
4-1BB x CLDN18.2
Mechanism
4-1BB agonists [+1]
Active Org.
I-Mab Biopharma US Ltd. [+1]
Originator Org.
I-MAB Biopharma Co., Ltd.
Active Indication
Pancreatic Ductal Carcinoma [+6]
Inactive Indication
Colorectal Cancer
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
10
Clinical Trials associated with I-Mab Biopharma US Ltd.
NCT04947033
/ RecruitingPhase 1
A Phase I Clinical Study Evaluating the Safety, Tolerability, MTD or MAD, PK, PD, and Antitumor Activity of TJ210001(a Fully Human C5aR Monoclonal Antibody) in Subjects With Advanced Solid Tumors
NCT05001347
/ CompletedPhase 2
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
NCT04900818
/ RecruitingPhase 1
A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors
100 Clinical Results associated with I-Mab Biopharma US Ltd.
Login to view more data
0 Patents (Medical) associated with I-Mab Biopharma US Ltd.
Login to view more data
100 Deals associated with I-Mab Biopharma US Ltd.
Login to view more data
100 Translational Medicine associated with I-Mab Biopharma US Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
2
1
Phase 2
Other
5
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free